News round-up for 22-26 May by DDW Digital Content Editor Diana Spencer.
The theme of our news review this week is money. Although Clarivate has reported a recent drop in investment in the industry, it is good to see companies raising money through funding rounds and investing in new facilities, as well as government support coming through to boost research in areas of urgent need.
The top stories:
Biopharma investment drops by nearly 50% in 2022
Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report.
$7.5M investment to target cancer and neurological diseases
PharmEnable has closed a pre-series A investment round of $7.5 million to develop the next generation of small molecule drugs against disease areas of high clinical need.
New London facility exceeds global plasmid DNA demand
Touchlight, a company providing DNA services and manufacturing enzymes, has completed the redevelopment and expansion of its UK manufacturing facility in London, UK.
UK government invests £39 million in AMR research
The UK government will invest up to £39 ($48) million in antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF).
Danish immunotherapy start-up raises €6M seed funding
Danish start-up InProTher has raised €6 million seed funding from private investors, with participation from the European Innovation Council (EIC) Fund.
